Cannabis, a complex plant: Different compounds and different effects on individuals

Therapeutic Advances in Psychopharmacology

Volumn 2, Issue 6, 2012, Pages 241-254

  Atakan, Zerrin ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

cannabidiol; Cannabis; delta 9 tetrahydrocannabinol; endocannabinoids; individual sensitivity to cannabis; tetrahydrocannabivarin

Indexed keywords

CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; CATECHOL METHYLTRANSFERASE; DELTA9(11) TETRAHYDROCANNABINOL; DOPAMINE TRANSPORTER; ENDOCANNABINOID; PROTEIN SERINE THREONINE KINASE;

ALLELE; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84997941865     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125312457586     Document Type: Review

References (108)

1. Anderson B. Rizzo M. Block R. Pearlson G. O’Leary D. (2010) Sex, drugs and cognition: effects of marijuana. J Psychoactive Drugs 42: 413–424.
2. Anglin D. Corcoran C. Brown A. Chen H. Lighty Q. Brook J. et al. (2012) Early cannabis use and schizotypal personality disorder symptoms from adolescence to middle adulthood. Schizophr Res 137: 45–49.
3. Arseneault L. Cannon M. Murray R. Poulton R. Caspi A. Moffitt T. (2002) Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 325: 1212–1213.
4. Atha M. (2005) Independent Drug Monitoring Unit (IDMU) Cannabis use in Britain. Available at: http://www.idmu.co.uk/
5. Athanasiou A. Clarke A. Turner A. Kumaran N. Vakilpour S. Smith P. et al. (2007) Cannabinoid receptor agonists are mitochondrial inhibitors: a unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. Biochem Biophys Res Commun 364: 131–137.
6. Barkus E. Stirling J. Hopkins R. Lewis S. (2006) Cannabis-induced psychosis-like experiences are associated with high schizotypy. Psychopathology 39: 175–178.
7. Batkai S. Pacher P. Osei-Hyiaman D. Radaeva S. Liu J. Harvey-White J. et al. (2004) Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 110: 1996–2002.
8. Benowitz N. Jones R. (1981) Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. J Clin Pharmacol 21: 214S–223S.
9. Bhattacharyya S. Atakan Z. Martin-Santos R. Crippa J. Kambeitz J. Prata D. et al. (2012) Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of delta-9-tetrahydrocannabinol on midbrain and striatal function. Mol Psychiatry 31 January (epub ahead of print).
10. Bhattacharyya S. Crippa J. Martin-Santos R. Winton-Brown T. Fusar-Poli P. (2009a) Imaging the neural effects of cannabinoids: current status and future opportunities for psychopharmacology. Curr Pharm Des 15: 2603–2614.
11. Bhattacharyya S. Fusar-Poli P. Borgwardt S. Martin-Santos R. Nosarti C. O’Carroll C. et al. (2009b) Modulation of mediotemporal and ventrostriatal function in humans by delta-9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry 66: 442–451.
12. Bhattacharyya S. Morrison P. Fusar-Poli P. Martin-Santos R. Borgwardt S. Winton-Brown T. et al. (2010) Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35: 764–774.
13. Borgwardt S. Allen P. Bhattacharyya S. Fusar-Poli P. Crippa J. Seal M. et al. (2008) Neural basis of Δ-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiatry 64: 966–973.
14. Callén L. Moreno E. Barraso-Chinea P. Moreno-Delgado D. Cortes A. Mallol J. et al. (2012) Cannabinoid receptors CB1 and CB2 form functional heteromers in the brain. J Biol Chem 287: 20851-20865.
15. Carlini E. Karniol I. Renault P. Schuster C. (1974) Effects of marihuana in laboratory animals and in man. Br J Pharmacol 50: 299–309.
16. Cascini F. Aiello C. Di Tanna G. (2011) Increasing delta-9-tetrahydrocannabinol (Δ-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev 5: 32-40.
17. Caspi A. Moffitt T. Cannon M. McClay J. Murray R. Harrington H. et al. (2005) Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 57: 1117–1127.
18. Costa B. Trovato A. Comellii F. Giagnoni G. Colleoni M. (2007) The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol 556: 75–83.
19. Crippa J. Derenusson G. Ferrari T. Wichert-Ana L. Duran F. Martin-Santos R. et al. (2011) Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: apreliminary report. J Psychopharmacol 25: 121–130.
20. Crippa J. Zuardi A. Martin-Santos R. Bhattacharyya S. Atakan Z. McGuire P. et al. (2009) Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol 7: 515–523.
21. Curran H. Brignell C. Fletcher S. Middleton P. Henry J. (2002) Cognitive subjective dose–response effects of acute oral delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology 164: 61–70.
22. Dakwar E. Nunes E. Bisaga A. Carpenter K. Mariani J. Sullivan M. et al. (2011) A comparison of independent depression and substance-induced depression in cannabis-, cocaine-, and opioid-dependent treatment seekers. Am J Addict 20: 441–446.
23. Degenhardt L. Coffey C. Carlin J. Swift W. Moore E. Patton G. (2010) Outcomes of occasional cannabis use in adolescence: 10-year follow-up study in Victoria, Australia. Br J Psychiatry 196: 290–295.
24. De Meijer E. Bagatta M. Carboni A. Crucitti P. Moliterni V. Ranalli P. et al. (2003) The inheritance of chemical phenotype in Cannabis sativa L. Genetics 63: 335–346.
25. Devane W. Dysarz F. Johnson M. Melvin L. Howlett A. (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34: 605–613.
26. Devane W. Hanus L. Breuer A. Pertwee R. Stevenson L. Griffin G. et al. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946–1949.
27. Dewey W. (1986) Cannabinoid pharmacology. Pharmacol Rev 38: 151–178.
28. Di Forti M. Morgan C. Dazzan P. Pariente C. Mondelli V. Marques T. et al. (2009) High-potency cannabis and the risk of psychosis. Br J Psychiatry 195: 488–491.
29. Di Marzo V. Piscitelli F. (2011) Gut feelings about the endocannabinoid system. Neurogastroenterol Motil 23: 391–398.
30. Di Marzo V. Piscitelli F. Mechoulam R. (2011) Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. Handb Exp Pharmacol 203: 75–104.
31. D’Souza D. Perry E. MacDougall L. Ammerman Y. Cooper T. Wu Y. et al. (2004) The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29: 1558–1572.
32. D’Souza D. Sewell R. Ranganathan M. (2009) Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci 259: 413–431.
33. EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) (2011) Annual Report 2011: The State of the Drug Problems in Europe. Lisbon: EMCDDA.
34. Fairman B. Anthony J. (2012) Are early-onset cannabis smokers at an increased risk of depression spells? J Affect Disord 138: 54–62.
35. Ferré S. Goldberg S. Lluis C. Franco R. (2009) Looking for the role of cannabinoid receptor heteromers in striatal function. Neuropharmacology 56(Suppl. 1): 226–234.
36. Fusar-Poli P. Crippa J. Bhattacharyya S. Borgwardt S. Allen P. Martin-Santos R. et al. (2009) Distinct effects of delta-9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 66: 95–105.
37. Gaoni Y. Mechoulam R. (1964) Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86: 1646–1647.
38. Gorelick D. Heishman S. (2006) Methods for clinical research involving cannabis administration. Methods Mol Med 123: 235–253.
39. Green B. Kavanagh D. Young R. (2003) Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev 22: 453–460.
40. Green K. (1998) Marijuana smoking vs cannabinoids for glaucoma therapy. Arch Ophthalmol 116: 1433–1437.
41. Hall W. Degenhardt L. (2007) Prevalence and correlates of cannabis use in developed and developing countries. Curr Opin Psychiatry 20: 393–397.
42. Hayakawa K. Mishima K. Hazekawa M. Sano K. Orito K. et al. (2008) Cannabidiol potentiates pharmacological effects of delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism. Brain Res 1888: 157–164.
43. Henquet C. Krabbendam L. Spauwen J. Kaplan C. Lieb R. Wittchen H. et al. (2004) Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 330: 11–14.
44. Henquet C. Krabbendam L. Spauwen J. Kaplan C. Lieb R. Wittchen H. et al. (2005) Prospective cohort study of cannabis use, predisposition for psychosis and psychotic symptoms in young people. BMJ 330: 11.
45. Howlett A. Barth F. Bonner T. Cabral G. Casellas P. Devane W. et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54: 161–202.
46. Iwamura H. Suzuki H. Ueda Y. Kaya T. Inaba T. (2001) In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J Pharmacol Exp Ther 296: 420–425.
47. Izzo A. (2004) Cannabinoids and intestinal motility: welcome to CB2 receptors. Br J Pharmacol 142: 1201–1202.
48. Juknat A. Rimmerman N. Levy R. Vogel Z. Kozela E. (2011) Cannabidiol affects the expression of genes involved in zinc homeostasis in BV-2 microglial cells. Neurochem Int 9 December (epub ahead of print).
49. Karniol I. Carlini E. (1973) Comparative studies in man and in laboratory animals on 8- and 9-trans-tetrahydrocannabinol. Pharmacology 9: 115–126.
50. Karniol I. Shirikawa I. Kasinski N. Pfefermen A. Carlini E. (1974) Cannabidiol interferes with the effects of delta-9-tetrahydrocannabinol in man. Eur J Pharmacol 28: 172–77.
51. Kenney S. Kekuda R. Prasad P. Leibach F. Devoe L. Ganapathy V. (1999) Cannabinoid receptors and their role in the regulation of the serotonin transporter in human placenta. Am J Obstet Gynecol 181: 491–497.
52. Lakhan S. Rowland M. (2009) Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. BMC Neurol 9: 59.
53. Li H. (1973) An archaeological and historical account of cannabis in China. Economic Botany 28: 437–448.
54. Mackie K. Stella N. (2006) Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J 8: E298–E306.
55. Marcellino D. Carriba P. Filip M. Borgkvist A. Frankowska M. Bellido I. et al. (2008) Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. Neuropharmacology 54: 815–823.
56. Matsuda L. Lolait S. Brownstein M. Young A. Bonner T. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561–564.
57. McGuire P. Jones P. Harvey I. Williams M. McGuffin P. Murray R. (1995) Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophr Res 15: 277–281.
58. Mechoulam R. Ben-Shabat S. Hanuš L. Ligumsky M. Kaminski N. Schatz A. et al. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83–90.
59. Mechoulam R. Hanus L. (2000) A historical overview of chemical research on cannabinoids. Chems Phys Lipids 108: 1–13.
60. Mechoulam R. Shvo Y. (1963) Hashish. I. The structure of cannabidiol. Tetrahedron 19: 2073–2078.
61. Molina-Holgado E. Vela J. Arévalo-Martin A. Almazán G. Molina-Holgado F. Borrell J. et al. (2002) Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signalling. J Neurosci 22: 9742–9753.
62. Moore T. Zammit S. Lingford-Hughes A. Barnes T. Jones P. Burke M. et al. (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370: 319–328.
63. Moreira F. Guimaraes F. (2005) Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol 512: 199–205.
64. Morgan C. Gardener C. Schafer G. Swan S. Demarchi C. Freeman T. et al. (2011) Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol Med 29: 1–10.
65. Morgan C. Schafer G. Freeman T. Curran H. (2010) Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Br J Psychiatry 197: 285–290.
66. Morrison P. Zois V. McKeown D. Lee T. Holt D. Powell J. et al. (2009) The acute effects of synthetic intravenous delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med 39: 1607–1616.
67. Munro S. Thomas K. Abu-Shaar M. (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61–65.
68. Navarro G. Carriba P. Gandia J. Ciruela F. Casadó V. Cortés A. et al. (2008) Detection of heteromers formed by cannabinoid CB2, dopamine D2, and adenosine A2A G-protein-coupled receptors by combining bimolecular fluorescence complementation and bioluminescence energy transfer. ScientificWorldJournal 8: 1088–1097.
69. Nicholson A. Turner C. Stone B. Robson P. (2004) Effect of delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol 24: 305–313.
70. Nunes E. Liu X. Samet S. Matseoane K. Hasin D. (2006) Independent versus substance-induced major depressive disorder in substance-dependent patients: observational study of course during follow-up. J Clin Psychiatry 67: 1561–1567.
71. Pagotto U. Marsicano G. Cota D. Lutz B. Pasquali R. (2006) The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27: 73–100.
72. Pamplona F. Takahashi R. (2012) Psychopharmacology of the endocannabinoids: far beyond anandamide. J Psychopharmacol 26: 7–22.
73. Parker L. Rock E. Limebeer C. (2011) Regulation of nausea and vomiting by cannabinoids. Br J Pharmacol 163: 1411–1422.
74. Pertwee R. (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74: 129– 180.
75. Pertwee R. (2006) The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (Lond) 30: S13–S18.
76. Pertwee R. (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153: 199–215.
77. Pertwee R. (2009) Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156: 397–411.
78. Pertwee R. (2010) Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem 17: 1360–1381.
79. Pertwee R. Howlett A. Abood M. Alexander S. Di Marzo V. Elphick M. (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 62: 588–631.
80. Peters B. de Koning P. Dingemans P. Becker H. Linszen D. de Haan L. (2009) Subjective effects of cannabis before the first psychotic episode. Aust N Z J Psychiatry 43: 1155–1162.
81. Pickel V. Chan J. Kearn C. Mackie K. (2006) Targeting dopamine D2 and cannabinoid-1 (CB1) receptors in rat nucleus accumbens. J Comp Neurol 495: 299–313.
82. Potter D. Clark P. Brown M. (2008) Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci 53: 90–94.
83. Raduner S. Majewska A. Chen J. Xie X. Hamon J. Faller B. et al. (2006) Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. J Biol Chem 281: 14192–14206.
84. Ramer R. Bublitz K. Freimuth N. Merkord J. Rohde H. Haustein M. et al. (2012) Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J 26: 1535-1548.
85. Rhee M. Vogel Z. Barg J. Bayewitch M. Levy R. Hanus L. et al. (1997) Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. J Med Chem 40: 3228–3233.
86. Russo E. B. (2001) Handbook of psychotropic herbs: a scientific analysis of herbal remedies for psychiatric conditions. Binghamton, NY: Haworth Press.
87. Russo E. Guy G. (2006) A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol andcannabidiol. Med Hypotheses 66: 234–246.
88. Russo E. Guy G. Robson P. (2007) Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem Biodivers 4: 1729–1743.
89. Showalter V. Compton D. Martin B. Abood M. (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278: 989–999.
90. Smieskova R. Fusar-Poli P. Allen P. Bendfeldt K. Stieglitz R. Drewe J. et al. (2010) Neuroimaging predictors of transition to psychosis – a systematic review and meta-analysis. Neurosci Biobehav Rev 34: 1207–1222.
91. Stirling J. Barkus E. Nabosi L. Irshad S. Roemer G. Schreudergoidheijt B. et al. (2008) Cannabis-induced psychotic-like experiences are predicted by high schizotypy. Confirmation of preliminary results in a large cohort. Psychopathology 41: 371–378.
92. Stone J. (2011) Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia? Ther Adv Psychopharmacol 1: 5–18.
93. Taylor A. Amoako A. Bambang K. Karasu T. Gebeh A. Lam P. et al. (2010) Endocannabinoids and pregnancy. Clin Chim Acta 411: 921–930.
94. Terry G. Liow J. Zoghbi S. Hirvonen J. Farris A. Lerner A. (2009) Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand. Neuroimage 48: 362–370.
95. Thomas H. (1996) A community survey of adverse effects of cannabis use, Drug Alcohol Depend 42: 201–207.
96. Torres S. Lorente M. Rodriguez-Fornés F. Hernandez-Tiedra S. Salazar M. Garcia-Taboada E. et al. (2011) A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 10: 90–103.
97. Tsou K. Brown S. Sanudo-Pena M. Mackie K. Walker J. (1998) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83: 393–411.
98. van Os J. Bak M. Bijl R. De Graaf R. Verdoux H. (2002) Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 156: 319–327.
99. van Os J. Kapur S. (2009) Schizophrenia. Lancet 374: 635–645.
100. van Waes V. Beverley J. Siman H. Tseng K. Steiner H. (2012) CB1 cannabinoid receptor expression in the striatum: association with corticostriatal circuits and developmental regulation. Front Pharmacol 3: 21.
101. van Winkel R., Genetic Risk and Outcome of Psychosis (GROUP) Investigators (2011) Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch Gen Psychiatry 68: 148–157.
102. Wallace M. Wiley J. Martin B. DeLorenzo R. (2001) Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol 428: 51–57.
103. Winton-Brown T. Allen P. Bhattacharrya S. Borgwardt S. Fusar-Poli P. Crippa J. et al. (2011) Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an fMRI study. Neuropsychopharmacology 36: 1340–1348.
104. Wood T. (1899) Cannabinol, part I. J Chem Soc 75: 20–36.
105. Zammit S. Allebeck P. Andreasson S. Lundberg I. Lewis G. (2002) Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 325: 1199–1201.
106. Zammit S. Spurlock G. Williams H. Norton N. Williams N. O’Donovan M. et al. (2007) Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use Br J Psychiatry 191: 402–407.
107. Zuardi A. Guimaraes F. (1997) Cannabidiol as an anxiolytic and antipsychotic. In: Mathre M. (ed), Cannabis in Medical Practice: A Legal, Historical and Pharmacological Overview of the Therapeutic Use of Marijuana. Jefferson, NC: McFarland, p. 133–141.
108. Zuardi A. Morais S. Guimaraes F. Mechoulam R. (1995) Antipsychotic effect of cannabidiol [letter]. J Clin Psychiatry 56: 485–486.